P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY

• J. Sanz-Caballer,
• J. Storek,
• G. Socié,
• D. Thirumalai,
• N. Guzman-Beccera,
• P. Xun,
• D. Kumar,
• N. Sadetsky,
• D. Dierickx,
• J. Reitan,
• A. Barlev,
• M. Mohty

Affiliations

J. Sanz-Caballer

1 Servicio de Hematología, Hospital Universitari i politècnic La Fe, Valencia, Spain

J. Storek

2 Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada

G. Socié

3 Service d’Hématologie-Greffe, Assistance Publique Hôpitaux de Paris-Hôpital Saint Louis, Paris, France

D. Thirumalai

4 Atara Biotherapeutics, Thousand Oaks, United States of America

N. Guzman-Beccera

4 Atara Biotherapeutics, Thousand Oaks, United States of America

P. Xun

4 Atara Biotherapeutics, Thousand Oaks, United States of America

D. Kumar

5 Ajmera Transplant Centre, University Health Network, Toronto, Canada

N. Sadetsky

6 Atara Biotherapeutics, South San Francisco, United States of America

D. Dierickx

7 Universitair Ziekenhuis Leuven, Leuven, Belgium

J. Reitan

8 RJM Group, LLC, Crown Point, United States of America

A. Barlev

6 Atara Biotherapeutics, South San Francisco, United States of America

M. Mohty

9 Hôpital Saint Antoine, Paris, France